Amy Kruse
InvestorGeneral Partner at Prime Movers Lab · Chief Investment Officer, Satori Neuro at Satori Capital · Board director at Gilgamesh Pharma · Board director at Motif Neurotech · Board director at Morphoceuticals
Washington DC-Baltimore Area
Writes $2M – $30M checks
About
Amy Kruse—PhD neuroscientist who led DARPA neuroscience and human-performance programs—guides neurotech (BCI, sensing) startups from board seats through scientific and regulatory complexity to enhance human performance.
Invests in
BiotechDeep TechEnergyHardwareMobility & TransportationSpace Tech
Board director at Gilgamesh Pharma
Intro paths
In turn, Amy can intro founders to Gilgamesh Pharma's investors below.
Gilgamesh Pharma's investors · 1
Co-founders at Gilgamesh Pharma
Board director at Motif Neurotech
Intro paths
In turn, Amy can intro founders to Motif Neurotech's investors below.
Motif Neurotech's investors · 9
Co-founders at Motif Neurotech
Board director at Morphoceuticals
Intro paths
In turn, Amy can intro founders to Morphoceuticals's investors below.
Morphoceuticals's investors · 1
Experience
- Satori CapitalGeneral Partner & Chief Investment Officer - Satori Neurocurrent2023 — present
- Prime Movers LabVenture Partnercurrent2022 — present
- Prime Movers LabGeneral Partner2021 — 2022
- Prime Movers LabPartner & Principal Biologist2020 — 2021
- Prime Movers LabAdvisor2020
- Gilgamesh PharmaceuticalsBoard Membercurrent2021 — present
- Paradromics Inc.Board Membercurrent2021 — present
- CognixionBoard Membercurrent2021 — present
- Attune Neurosciences, Inc.Board Membercurrent2021 — present
- OpenBCIStrategic Advisorcurrent2020 — present
- Sattva ScienceFounder & Presidentcurrent2020 — present
- The Stimson CenterFounding Council Member - Loomis Innovation Councilcurrent2018 — presentWashington D.C. Metro Area
- IVIVA Medical IncBoard Member2021 — 2023
- Iridia, Inc.Board Member & Compensation Committee2021 — 2022
- Optios (formerly Platypus Institute)Chief Scientific Officer2017 — 2020
- Cubic CorporationStrategic Advisor2017
- Cubic CorporationChief Technology Officer2015 — 2017
- IntificVice President of Innovation2014 — 2017
- IntificVice President2012 — 2014Alexandria, VA
- IntificExecutive Director, Neuroscience Division2010 — 2012
- DARPAProgram Manager2005 — 2010
- Strategic AnalysisScientist2002 — 2005
Skills & more
+12 more
New Business DevelopmentHealthcareBusiness StrategyInvestmentsFundraisingProgram ManagementNeuroscienceProposal WritingR&DScienceSystems EngineeringDoDFrom Amy's professional profile.
Deals · 6
Gilgamesh PharmaBoard seat
via Prime Movers Lab · filed Mar 2026 · $15M raise
CognixionBoard seat
via Prime Movers Lab · filed Jan 2025 · $6M raise
Motif NeurotechBoard seat
via Prime Movers Lab · filed Jan 2024 · $21.6M raise
MorphoceuticalsBoard seat
via Prime Movers Lab · filed Jan 2023 · $9.8M raise
Dodo OmniDataBoard seat
via Prime Movers Lab · filed Nov 2021 · $6M raise
Gilgamesh PharmaceuticalsBoard seat
via Prime Movers Lab · filed May 2021 · $34.7M raise
Attribution from SEC filings, press coverage, and firm rosters.
Other disclosed investments
Board seats
Per SEC Form D filings.
Colleagues at Prime Movers Lab
Network8
Investors connected to Amy in public investor directories — a warm-intro map.
Frequently asked questions
- Who is Amy Kruse?
- Amy Kruse—PhD neuroscientist who led DARPA neuroscience and human-performance programs—guides neurotech (BCI, sensing) startups from board seats through scientific and regulatory complexity to enhance human performance.
- Where does Amy Kruse work?
- Amy Kruse is General Partner at Prime Movers Lab and Board director at Gilgamesh Pharma and Board director at Motif Neurotech and Board director at Morphoceuticals.
- What does Amy Kruse invest in?
- Amy Kruse invests in Biotech, Deep Tech, Energy, Hardware, Mobility & Transportation, Space Tech.
- What check size does Amy Kruse write?
- Amy Kruse typically writes checks of $2M – $30M.
- What boards does Amy Kruse sit on?
- Amy Kruse holds tracked board seats at Cognixion, Dodo OmniData, Gilgamesh Pharma, Gilgamesh Pharmaceuticals, Morphoceuticals, Motif Neurotech, Paradromics Turning Data Into Medicine.
- Where did Amy Kruse go to school?
- Amy Kruse studied at University of Illinois Urbana-Champaign (Ph.D., Neuroscience); University of Illinois Urbana-Champaign (B.S., Cell and Structural Biology); Northwestern University (Biomedical Engineering).
Same school
Also attended University of Illinois Urbana-Champaign421
+ 415 more
Also attended Northwestern University352
+ 346 more
Shared employers
Also worked at Prime Movers Lab26
+ 20 more
